Furthermore, the therapeutic use of a CCR2/CCR5 antagonist reduced monocyte recruitment to the liver in models of steatohepatitis and thus reduced insulin resistance, NASH activity and fibrosis [64]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.